COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Blepharospasm Patient Survey for Patients With Blepharospasm

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01686061
Recruitment Status : Completed
First Posted : September 17, 2012
Last Update Posted : April 8, 2014
Information provided by (Responsible Party):
Merz North America, Inc.

Brief Summary:
The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.

Condition or disease Intervention/treatment
Blepharospasm Other: No intervention- only one time survey

Detailed Description:
This study is open to males and females > 18 years and < 81 years with a clinical diagnosis of blepharospasm.

Layout table for study information
Study Type : Observational
Actual Enrollment : 124 participants
Official Title: Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients With Blepharospasm
Study Start Date : September 2012
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2013

Group/Cohort Intervention/treatment
Blepharospasm Survey Group Other: No intervention- only one time survey

Primary Outcome Measures :
  1. Botulinum Toxin Treatment Information [ Time Frame: This is a single, structured interview about experiences with Botulinum Toxins ]
    The following information for patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA, or onabotulinumtoxinA treatment is collected: (1) botulinum treatment information such as intervals for botulinum injections, physician's rationale for injection interval, overall experience with botulinum toxin injections (onset, maximum effect, decline of effect), current injection cycle experience (current satisfaction, satisfaction at maximum effect, and visual analog scale (VAS) of current health status); and (2) disability status using the Blepharospasm Disability Index (BSDI) and the Jankovic Rating Scale (JRS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 81 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA treatment.

Inclusion Criteria:

  • Male or female subject aged > 18 years and < 81 years
  • Documented clinical diagnosis of blepharospasm
  • Currently receiving incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA

Exclusion Criteria:

  • Previous treatment with rimabotulinumtoxinB in the last 2 treatment cycles

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01686061

Layout table for location information
United States, California
Merz Investigative Site #0007
Fountain Valley, California, United States, 92708
United States, Florida
Merz Investigative Site # 0002
Sarasota, Florida, United States, 34239
United States, Massachusetts
Merz Investigative Site # 0001
Boston, Massachusetts, United States, 02111
United States, North Carolina
Merz Investigative Site #003
Durham, North Carolina, United States, 27710
United States, Ohio
Merz Investigative Site # 0006
Columbus, Ohio, United States, 43215
Sponsors and Collaborators
Merz North America, Inc.
Layout table for investigator information
Study Director: Micki Seoane Merz Pharmaceutical, LLC
Layout table for additonal information
Responsible Party: Merz North America, Inc. Identifier: NCT01686061    
Other Study ID Numbers: MUS6020100920
First Posted: September 17, 2012    Key Record Dates
Last Update Posted: April 8, 2014
Last Verified: April 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Eyelid Diseases
Eye Diseases